At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical ...
In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...
Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...
At Envision Summit 2026 in Puerto Rico, Inder Paul Singh, MD, discussed office-based surgery and the evolving concept of interventional glaucoma in a CE Spotlight Symposium with Mary Qiu, MD, and ...
A discussion of his situation led to the selection of the enVista Envy IOL. One month postoperatively, the patient achieved 20/20–2 vision bilaterally, with a small amount of myopia in the right eye ...
More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...
IOLs: What Every Surgeon Needs to Know is an editorially independent video and podcast series from Ophthalmology Times, ...
Larissa Camejo, MD: I’m a glaucoma specialist and the owner of a solo private practice in Palm Beach Gardens, Florida. Our ...
Rahul Tonk, MD, MBA attended Envision Summit 2026 to present on refractive surgery, dry eye, and ocular surface disease. In the CE Spotlight Symposium titled “Emerging Therapeutic Advancements in Dry ...
Age-related macular degeneration (AMD) is associated with aging and typified by a wide range of symptoms from vision impairment to blindness. 1 Once diagnosed, it has a profound effect on patients by ...
As the use of glaucoma drainage implants (GDIs) continues to expand in clinical practice, surgeons are becoming more attuned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results